CERo Therapeutics (NASDAQ:CERO – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Institutional and Insider Ownership
29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares CERo Therapeutics and Xenetic Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CERo Therapeutics | N/A | N/A | -$8.30 million | ($102.61) | 0.00 |
| Xenetic Biosciences | $2.50 million | 2.11 | -$3.96 million | ($2.05) | -1.12 |
Xenetic Biosciences has higher revenue and earnings than CERo Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for CERo Therapeutics and Xenetic Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CERo Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Xenetic Biosciences | 1 | 1 | 0 | 0 | 1.50 |
CERo Therapeutics presently has a consensus price target of $45.00, indicating a potential upside of 99,018.94%. Given CERo Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than Xenetic Biosciences.
Profitability
This table compares CERo Therapeutics and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CERo Therapeutics | N/A | N/A | -209.40% |
| Xenetic Biosciences | -110.42% | -64.66% | -54.63% |
Volatility & Risk
CERo Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for CERo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CERo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
